Tags

Type your tag names separated by a space and hit enter

The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis.
Neurol Sci. 2021 Aug; 42(8):3093-3099.NS

Abstract

BACKGROUND

The prevalence of COVID-19 is different in studies conducted in different countries. The aim of this systematic review and meta-analysis is to estimate the pooled prevalence of COVID-19 in patients with MS.

METHODS

Two independent researchers independently searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as (((coronavirus OR Wuhan coronavirus OR novel coronavirus OR coronavirus disease OR COVID-19 OR 2019 novel coronavirus infection OR 2019-nCOV OR severe acute respiratory syndrome coronavirus 2 OR SARS-CoV-2) AND (Multiple Sclerosis OR Sclerosis, Multiple) OR Sclerosis, Disseminated) OR Disseminated Sclerosis) OR MS (Multiple Sclerosis)) OR Multiple Sclerosis, Acute Fulminating).

RESULTS

We found 1466 articles by literature search, and after deleting duplicates, 1029 remained. Twelve articles remained for meta-analysis. Totally, 101,462 patients were evaluated and the total number of possible/confirmed cases was 1394. Mean age ranged from 35 to 54 years. Totally, 49 patients died. The pooled prevalence of suspected COVID-19 in MS patients was 4% (95% CI: 3-4%) (I2 = 98.5%, P < 0.001). The pooled prevalence of hospitalization in infected cases was 10% (95% CI: 7-12%) (I2 = 95.6%, P < 0.001). The pooled prevalence of death in hospitalized cases was 4% (95% CI: 1-6%) (I2 = 82.4%, P < 0.001).

CONCLUSION

Hospitalization rate is higher among MS patients based on COVID-19 infection while the pooled infection rate is estimated as 4%.

Authors+Show Affiliations

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. m.ghajarzadeh@gmail.com. Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran. m.ghajarzadeh@gmail.com.

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

34100130

Citation

Moghadasi, Abdorreza Naser, et al. "The Prevalence of COVID-19 Infection in Patients With Multiple Sclerosis (MS): a Systematic Review and Meta-analysis." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 42, no. 8, 2021, pp. 3093-3099.
Moghadasi AN, Mirmosayyeb O, Barzegar M, et al. The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Neurol Sci. 2021;42(8):3093-3099.
Moghadasi, A. N., Mirmosayyeb, O., Barzegar, M., Sahraian, M. A., & Ghajarzadeh, M. (2021). The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 42(8), 3093-3099. https://doi.org/10.1007/s10072-021-05373-1
Moghadasi AN, et al. The Prevalence of COVID-19 Infection in Patients With Multiple Sclerosis (MS): a Systematic Review and Meta-analysis. Neurol Sci. 2021;42(8):3093-3099. PubMed PMID: 34100130.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis. AU - Moghadasi,Abdorreza Naser, AU - Mirmosayyeb,Omid, AU - Barzegar,Mahdi, AU - Sahraian,Mohammad Ali, AU - Ghajarzadeh,Mahsa, Y1 - 2021/06/07/ PY - 2021/04/09/received PY - 2021/05/31/accepted PY - 2021/6/9/pubmed PY - 2021/8/10/medline PY - 2021/6/8/entrez KW - COVID-19 KW - Multiple sclerosis KW - Prevalence SP - 3093 EP - 3099 JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol Sci VL - 42 IS - 8 N2 - BACKGROUND: The prevalence of COVID-19 is different in studies conducted in different countries. The aim of this systematic review and meta-analysis is to estimate the pooled prevalence of COVID-19 in patients with MS. METHODS: Two independent researchers independently searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as (((coronavirus OR Wuhan coronavirus OR novel coronavirus OR coronavirus disease OR COVID-19 OR 2019 novel coronavirus infection OR 2019-nCOV OR severe acute respiratory syndrome coronavirus 2 OR SARS-CoV-2) AND (Multiple Sclerosis OR Sclerosis, Multiple) OR Sclerosis, Disseminated) OR Disseminated Sclerosis) OR MS (Multiple Sclerosis)) OR Multiple Sclerosis, Acute Fulminating). RESULTS: We found 1466 articles by literature search, and after deleting duplicates, 1029 remained. Twelve articles remained for meta-analysis. Totally, 101,462 patients were evaluated and the total number of possible/confirmed cases was 1394. Mean age ranged from 35 to 54 years. Totally, 49 patients died. The pooled prevalence of suspected COVID-19 in MS patients was 4% (95% CI: 3-4%) (I2 = 98.5%, P < 0.001). The pooled prevalence of hospitalization in infected cases was 10% (95% CI: 7-12%) (I2 = 95.6%, P < 0.001). The pooled prevalence of death in hospitalized cases was 4% (95% CI: 1-6%) (I2 = 82.4%, P < 0.001). CONCLUSION: Hospitalization rate is higher among MS patients based on COVID-19 infection while the pooled infection rate is estimated as 4%. SN - 1590-3478 UR - https://www.unboundmedicine.com/medline/citation/34100130/The_prevalence_of_COVID_19_infection_in_patients_with_multiple_sclerosis__MS_:_a_systematic_review_and_meta_analysis_ L2 - https://link.springer.com/10.1007/s10072-021-05373-1 DB - PRIME DP - Unbound Medicine ER -